Clinical Profile, Molecular Landscape, and Outcomes of Myelofibrosis in Lebanon: Real-World Data (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-469; Location: LEVEL 3, HALL B3; "The most frequently used therapies were ruxolitinib (57.8%) and hydroxyurea (22.1%). The clinical and molecular features of MF in this cohort were broadly consistent with published data, but real-world differences in treatment delivery and continuity were evident. These findings highlight the value of dedicated MPN programs and the importance of regional data to understand biological and health care system factors influencing MF outcomes. ASXL1: ASXL transcriptional regulator 1, DIPSS: Dynamic International Prognostic Scoring System, JAK2: Janus kinase 2, MPN: myeloproliferative neoplasms, TET2: tet methylcytosine dioxygenase 2."
Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Chronic Eosinophilic Leukemia • Hematological Malignancies • Leukemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • ASXL1 • JAK2 • TET2
|
|
Hiba Smaily MD; Hiam Fakhreddine MD; Nour Moukalled MD; Jean El Cheikh MD; Ali Bazarbachi MD; Iman Abou Dalleh MD
|